nervous system drugs are also one of the categories of drugs whose sales increase most rapidly in recent years. In 2002, nervous system drugs occupied 5.9% of the whole pharmaceutical market share, and the total sales amount increased by 9.4%.
With the increasing trend of urbanization and aging, the elderly population in China has exceeded 120 million, and the incidence of elderly diseases, especially mental diseases, is also increasing year by year. With the increase of residents' income, the elderly's demand for quality of life also increases. The trend has also led to a surge in demand for drugs to treat mental illnesses such as Alzheimer's. In the drug classification of WHO, psychoactive drugs and nootropics are combined into one category. We made a brief analysis of the development trend of these drugs through the clinical medication data collected by Chinese Pharmaceutical Association from more than 300 key hospitals in China.
The overall market size of these drugs is about 1.22 billion yuan. In 2002, the amount of sales increased by only 5.0%, but the quantity of sales increased by 11.2%. The main reason why the amount of sales did not rise in line with the quantity of sales is that the main strains of the drugs, such as piracetam, cobalt-bin ceramide and ginkgo leaves, In 2002, sales unit prices fell sharply due to bidding. Ginkgo biloba preparations occupy the largest market share, with a market share of over 1/3, ganglioside esters and cobalt bin amide combined take up nearly 1/3, cetam drugs such as piracetam occupy nearly 10%, and the rest of the drugs each account for less than 5%. At present, ginkgo leaf production enterprises more than 20, piracetam production enterprises more than 70, have entered the stage of price competition, profit repeatedly diluted.
Among the first-line varieties, except for Ginkgo biloba, the growth of other varieties was weak, especially the traditional variety piracetam was subjected to bidding